Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Boca Pharmacal Receives FDA Approval for Generic Version of PanlorSS
April 29th, 2007
Boca Pharmacal, Inc. made two major announcements today with the U.S. Food and Drug Administration granting its final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of and Panlor(R)SS (Acetaminophen, Caffeine and Dihydrocodeine) and the signing of an exclusive marketing and distribution agreement with Tedor Pharma Inc. for Didrex(R) (Benzphetamine Hydrochloride). Boca Pharmacal also announced that the company plans to launch both products immediately. Exclusive Marketing Agreement with Tedor to Market Generic Version of Didrex(R) The agreement with Tedor Pharma provides Boca Pharmacal with exclusive...
Source: Medical Letter on the CDC & FDA (2007-04-29)
|
